Explore how oligonucleotides are reshaping therapeutics, diagnostics and CRISPR with rapid, scalable and personalized ...

Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious ...

A new scalable technique enables the generation of human kidney organoids by integrating them into perfused pig kidneys.

CRISPR-based epigenetic editing is used in a cell-type-specific, locus-restricted and temporally controllable manner in the adult mouse brain to modulate memory expression. Analysis of two large ...

The $12.5 billion acquisition of Avidity Biosciences Inc. by Novartis AG strengthens the company’s neuroscience pipeline and marks the second biggest deal that’s been announced this year. San ...

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy rating on the shares after the company paused ...

Advances in cancer immunotherapy from immune checkpoint modulation to adoptive cell transfer of tumour-infiltrating ...

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.